Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy
Sadly most women who have ovarian cancer will have recurrent disease. With platinum chemotherapy treatment the recurrence rate is about 70% within two years for women with advanced disease. When recurrence occurs the usual second line treatment is repeat platinum chemo, often with good effect.
In the last three years or so a new strategy of maintenance therapy using PARPi drugs such as Olaparib has become common. This study looks at the effect this maintenance has on subsequent effectiveness of repeat platinum chemo.
Unfortunately the effect of maintenance Olaparib therapy is to significantly reduce the benefit of a second platinum chemo course. The mechanism of this is not known but there is speculation that reactivation of DNA repair processes, which is the usual cause of PARPi resistance, may be why, as platinum chemo acts by DNA disruption.
No comments:
Post a Comment